Cargando…

2838. Safety and Immunogenicity of a gp120-CD4 Chimeric Subunit Vaccine: A Phase 1a Randomized Controlled Trial

BACKGROUND: A primary challenge for HIV vaccine development is to raise antiviral antibodies capable of recognizing highly variable viral antigens. The full-length single chain (FLSC) gp120-CD4 chimeric protein was designed to present a highly conserved CD4-induced HIV-1 envelope structure that evok...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chua, Joel V, Davis, Charles, Nelson, Amy, Lam, Ka Wing J, Mutumbi, Lydiah, Stafford, Kristen A, Gilliam, Bruce, DeVico, Anthony L, Lewis, George K, Sajadi, Mohammad M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809108/ http://dx.doi.org/10.1093/ofid/ofz359.143

Ejemplares similares

Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial
por: Chua, Joel V., et al.
Publicado: (2021)

Antigenic Properties of the Human Immunodeficiency Virus Envelope Glycoprotein Gp120 on Virions Bound to Target Cells
por: Mengistu, Meron, et al.
Publicado: (2015)

Patterns of conserved gp120 epitope presentation on attached HIV-1 virions
por: Mengistu, Meron, et al.
Publicado: (2017)

A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen
por: Vijayan, Aneesh, et al.
Publicado: (2015)

Immunogenicity of the outer domain of a HIV-1 clade C gp120
por: Chen, Hongying, et al.
Publicado: (2007)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials
por: Yu, Bin, et al.
Publicado: (2012)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector
Publicado: (2020)

Novel findings from 2,838 Adult Brains on Sex Differences in Gray Matter Brain Volume
por: Lotze, Martin, et al.
Publicado: (2019)

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation
por: Kumar, R, et al.
Publicado: (2012)

Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design
por: Hu, Duoyi, et al.
Publicado: (2017)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Designs and Characterization of Subunit Ebola GP Vaccine Candidates: Implications for Immunogenicity
por: Agnolon, Valentina, et al.
Publicado: (2020)

Short‐duration treatment with the novel non‐nucleoside inhibitor CDI‐31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open‐label study
por: Chua, Joel V., et al.
Publicado: (2020)

Transforming epitope-specific gp120 monomer-based probes into immunogens with N-linked glycan masking
por: Chuang, G, et al.
Publicado: (2012)

Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region
por: Tolbert, William D., et al.
Publicado: (2016)

Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site
por: Dai, K, et al.
Publicado: (2012)

Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation
Publicado: (1996)

2838. Clinical Application and Validation of a Predictive Antimicrobial Resistance Risk Categorization Framework for Patients with Uncomplicated Urinary Tract Infection
por: Shields, Ryan K, et al.
Publicado: (2023)

Antigen processing sites in gp120 are conserved across HIV virus clades
por: Yu, B, et al.
Publicado: (2012)

Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies
por: Doran, Rachel C., et al.
Publicado: (2018)

Physiological Corticosterone Attenuates gp120-Mediated Microglial Activation and Is Associated with Reduced Anxiety-Like Behavior in gp120-Expressing Mice
por: Moss, Emaya M., et al.
Publicado: (2023)

The immunogenicity of chimeric antibodies
Publicado: (1989)

Eliciting neutralizing antibodies with gp120 outer domain
por: Qin, Y, et al.
Publicado: (2012)

Internalization and Axonal Transport of the HIV Glycoprotein gp120
por: Berth, Sarah, et al.
Publicado: (2015)

Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters
por: Azizi, Ali, et al.
Publicado: (2006)

Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines
por: Wang, Shixia, et al.
Publicado: (2017)

Allosteric Modulation of the HIV-1 gp120-gp41 Association Site by Adjacent gp120 Variable Region 1 (V1) N-Glycans Linked to Neutralization Sensitivity
por: Drummer, Heidi E., et al.
Publicado: (2013)

Durable cytotoxic immune responses against gp120 elicited by recombinant SV40 vectors encoding HIV-1 gp120 ± IL-15
por: McKee, Hayley J, et al.
Publicado: (2004)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface
por: Torrents de la Peña, Alba, et al.
Publicado: (2021)

NMR spectroscopy of HIV-1 gp120 outer domain
por: Sastry, M, et al.
Publicado: (2012)

Behavioral Evidence for a Tau and HIV-gp120 Interaction
por: Vijayan, Murali, et al.
Publicado: (2022)

Structural Basis for Species Selectivity in the HIV-1 gp120-CD4 Interaction: Restoring Affinity to gp120 in Murine CD4 Mimetic Peptides
por: Kassler, Kristin, et al.
Publicado: (2011)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
por: Sanders, Rogier W, et al.
Publicado: (2004)

Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response
por: Visciano, Maria Luisa, et al.
Publicado: (2008)

Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies
por: Rusert, Peter, et al.
Publicado: (2011)

Deletion of the Highly Conserved N-Glycan at Asn260 of HIV-1 gp120 Affects Folding and Lysosomal Degradation of gp120, and Results in Loss of Viral Infectivity
por: Mathys, Leen, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_blal07pc16bncj329mdh1qsc0f